Published online Mar 14, 2015. doi: 10.3748/wjg.v21.i10.3100
Peer-review started: August 14, 2014
First decision: September 15, 2014
Revised: September 18, 2014
Accepted: October 14, 2014
Article in press: October 15, 2014
Published online: March 14, 2015
Processing time: 214 Days and 19 Hours
AIM: To explore effects of nonselective beta-blockers (NSBBs) in cirrhotic patients with no or small varices.
METHODS: The PubMed, EMBASE, Science Direct, and Cochrane library databases were searched for relevant papers. A meta-analysis was performed using ORs with 95%CI as the effect sizes. Subgroup analysis was conducted according to the studies including patients without varices and those with small varices.
RESULTS: Overall, 784 papers were initially retrieved from the database searches, of which six randomized controlled trials were included in the meta-analysis. The incidences of large varices development (OR = 1.05, 95%CI: 0.25-4.36; P = 0.95), first upper gastrointestinal bleeding (OR = 0.59, 95%CI: 0.24-1.47; P = 0.26), and death (OR = 0.70, 95%CI: 0.45-1.10; P = 0.12) were similar between NSBB and placebo groups. However, the incidence of adverse events was significantly higher in the NSBB group compared with the placebo group (OR = 3.47, 95%CI: 1.45-8.33; P = 0.005). The results of subgroup analyses were similar to those of overall analyses.
CONCLUSION: The results of this meta-analysis indicate that NSBBs should not be recommended for cirrhotic patients with no or small varices.
Core tip: Nonselective beta-blockers have been recommended for the primary and secondary prophylaxis of variceal bleeding in cirrhotic patients with high-risk varices and those with previous bleeding. However, their role remains uncertain in cirrhotic patients with no or small varices. Our meta-analysis demonstrates that the use of nonselective beta-blockers should not be recommended for cirrhotic patients with no or small varices.